妈妈的职业免费电影,天地无伦在线观看视频,为你存在歌词

Evolocumab

NMR下載 COA and HPLC MSDS下載
names：
Evolocumab
CAS號：
1256937-27-5
MDL Number：
MF(分子式)： MW(分子量)：
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

貨品編碼	規格	純度	價格 (￥)	現價(￥)	特價(￥)	庫存描述	數量	總計 (￥)
DBK501942-500mg	500mg		￥ 0.00	￥ 0.00		Get quote	- +	￥ 0.00
DBK501942-100mg	100mg		￥ 0.00	￥ 0.00		Get quote	- +	￥ 0.00

大包裝詢價提供各種包裝，敬請垂詢
收藏商品商品點評加入購物車立即購買

快速詢價

收起

你想詢價的產品

*產品名稱：

CAS號：

產品編號：

需求描述：

請準確填寫您的聯系方式，以便為您提供最好的服務。

*公司名稱：

*電子郵箱：

聯系人：

*電話：

*驗證碼：

詢價

中文別名
英文別名	Evolocumab
CAS號	1256937-27-5
Inchi
InchiKey
分子式 Formula
分子量 Molecular Weight
溶解度Solubility
性狀	Liquid
儲藏條件 Storage conditions

Evolocumab使用注意事項：
1.實驗前需戴好防護眼鏡，穿戴防護服和口罩，佩戴手套，避免與皮膚接觸。
2.實驗過程中如遇到有毒或者刺激性物質及有害物質產生，必要時實驗操作需要手套箱內完成以免對實驗人員造成傷害。
3.取樣品的移液槍頭需及時更換，必要時為避免交叉污染盡可能選擇濾芯吸頭。
4.稱量藥品時選用稱量紙，并無風處取藥和稱量以免揚撒，試劑的容器使用前務必確保干凈，并消毒。
5.取藥品時盡量采用多個藥勺分別使用，使用后清洗干凈。
6.實驗后產生的廢棄物需分類存儲，并交于專業生物廢氣物處理公司處理，以免造成環境污染。
大規格定制：定制產品請將信息發送至sales@bio-fount.com。
Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

產品說明	Organic Acids
Introduction
Application1	Evolocumab is a human IgG monoclonal antibody which targets PCSK9 (proprotein convertase subtilisin/kexin type 9). PCSK9 is a serine protease produced by the liver which binds LDL receptors and creates a complex to be targeted for lysosomal degradation. LDL receptors typically bind LDL-cholesterol ("bad" cholesterol) for cellular reuptake, therefore the formation of these complexes with PCSK9 inhibits LDL receptor recycling to the cell surface, resulting in decreased cellular reuptake of LDL-C and increased levels of free LDL-C in the plasma. Individuals with familial hypercholesterolemia often may have "gain of function" mutations in the PCSK9 molecules in their body, resulting in increased LDL-C plasma levels and a consequent cardiovascular risk. Evolocumab is able to bind both the normal PCSK9 and the "gain of function" mutant, D374Y. The exact mechanism of the binding has not been published, however the precursor molecule, mAb1, is indicative of the interaction. The mAb1 molecule binds on the catalytic site of PCSK9 next to the binding site for the LDL receptor and creates hydrogen bonds and hydrophobic interactions, resulting in the steric inhibition of binding between PCSK9 and the LDL receptor. Because the formation of complexes between LDL receptor and PCSK9 are prevented, the internalized LDL receptors are less likely to be degrated by lysosomes and may recycle to the surface of the cell to serve their function of removing LDL from the blood.
Application2
Application3